...
首页> 外文期刊>Trends in molecular medicine >Oligodendrocyte NMDA receptors: a novel therapeutic target.
【24h】

Oligodendrocyte NMDA receptors: a novel therapeutic target.

机译:少突胶质细胞NMDA受体:一种新型治疗靶标。

获取原文
获取原文并翻译 | 示例

摘要

Excessive glutamate signaling can lead to excitotoxicity, a phenomenon whereby over-activation of glutamate receptors initiates neuronal death. In recent years, it has been shown that glutamate can be toxic to white-matter oligodendrocytes. Up to recently, the prevailing view was that oligodendrocyte excitotoxicity is mediated by alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and kainate glutamate receptor types. Three recent studies have shown that oligodendrocytes also express N-methyl-D-aspartate (NMDA) receptors, which are activated under pathological conditions. Thus, NMDA receptors seem to be a promising target for the development of new drugs to treat white-matter damage in acute and chronic diseases.
机译:过量的谷氨酸信号传导会导致兴奋性毒性,这种现象使谷氨酸受体的过度活化引发神经元死亡。近年来,已经表明谷氨酸对白质少突胶质细胞有毒性。直到最近,普遍的观点是少突胶质细胞的兴奋性毒性是由α-氨基-3-羟基-5-羟基-5-甲基-4-异恶唑丙酸(AMPA)和氨基甲酸酯谷氨酸受体类型介导的。最近的三项研究表明,少突胶质细胞还表达N-甲基-D-天冬氨酸(NMDA)受体,这些受体在病理条件下被激活。因此,NMDA受体似乎是开发用于治疗急性和慢性疾病中的白质损伤的新药物的有希望的靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号